EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sufentanil use in critically ill children: a single-center experience

Seong Jong Park, Won Kyoung Jhang

Archives of Pediatric Critical Care · 2023

DOI: 10.32990/apcc.2023.00017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pediatric Critical Care, 2023. Verfasst von Seong Jong Park und 1 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Critically ill children often require pain management or sedation due to their underlying conditions or the need for intensive care.However, the available drug options and their clinical reliability are frequently limited for these patients.This study explored the utility of sufentanil as an analgosedative in critically ill pediatric patients, drawing on clinical experience.

Methods

This single-center retrospective observational cohort study included patients under 19 years of age admitted to the pediatric intensive care unit (PICU) in a tertiary care children's hospital between March 2021 and September 2022, in whom sufentanil was used as the first-choice continuous analgosedative drug.

Results

In total, 225 patients were included.The most common reason for PICU admission was postoperative care (34.7%), followed by respiratory failure (20.0%), and cardiac problems (17.3%).The initial median starting and maximum doses of sufentanil were 0.5 μg/kg/hr (interquartile range [IQR], 0.3-1.0).The median durations of sufentanil use, mechanical ventilation support, and PICU stay were 1 days (IQR, 4-12), 6 days (IQR, 1-17) and 9 days (IQR, 5-27), respectively.In 199 (88.4%) patients, an appropriate analgesia/sedation level was achieved with sufentanil alone.However, 26 patients required additional drugs such as midazolam and ketamine infusion after administering the maximum dose of sufentanil, indicating the necessity for supplementary agents.No significant adverse effects or withdrawal symptoms were associated with sufentanil use.

Conclusion

Sufentanil may be a promising option for analgesia/sedation in critically ill pediatric patients, as it demonstrated no significant side effects or withdrawal symptoms.However, larger-scale randomized controlled research is necessary to generalize these results.

Zitieren

APA

Park, S. J., & Jhang, W. K. (2023). Sufentanil use in critically ill children: a single-center experience. Archives of Pediatric Critical Care. https://doi.org/10.32990/apcc.2023.00017

Vancouver

Park SJ, Jhang WK. Sufentanil use in critically ill children: a single-center experience. Archives of Pediatric Critical Care. 2023. doi:10.32990/apcc.2023.00017

BibTeX
@article{Park2023,
  author = {Park, Seong Jong and Jhang, Won Kyoung},
  title = {Sufentanil use in critically ill children: a single-center experience},
  journal = {Archives of Pediatric Critical Care},
  year = {2023},
  doi = {10.32990/apcc.2023.00017}
}
Kostenlos starten →